bioAffinity Technologies faces Nasdaq delisting risk after shares trade below $1 bid-price minimum
BIAF•Nasdaq staff determination on bid-price rule
bioAffinity Technologies received a Nasdaq staff determination for failing the $1 minimum bid price rule, with shares below $1 for 30 sessions.
Nasdaq denied the standard 180-day cure period because of a 1-for-30 reverse split on Sept. 19, 2025.
An appeal due Aug. 6, 2026 would stay delisting pending a Nasdaq hearings panel decision.
Related News
CO2 Energy Transition Corp - Brady Rodgers Resigns As President, CEO, And Director Effective July 27, 2026 - SEC Filing
NOEM•
Certain Blackrock Closed-End Funds Announce Estimated Sources Of Distributions
BLK•
